Calithera Biosciences, Inc.
CALA · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | 0.14 | -0.10 |
| FCF Yield | -268.78% | -135.24% | -24.97% | -29.15% |
| EV / EBITDA | 0.20 | 0.06 | -2.69 | -2.48 |
| Quality | ||||
| ROIC | -172.82% | -213.61% | -82.34% | -61.67% |
| Gross Margin | 0.00% | 85.29% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.10 | 0.58 | 0.94 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 34.17% | 21.25% | -7.14% | -21.05% |
| Safety | ||||
| Net Debt / EBITDA | 0.62 | 0.50 | 1.14 | 0.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -3.83 |
| Cash Conversion Cycle | -192.91 | -929.04 | -389.20 | -501.31 |